Belite Bio, Inc
NASDAQ:BLTE · NASDAQ Capital Market
+$0.46 today
Vol 0.25M · Avg 0.17M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-10.1%
avg 7.6%
ROIC
-10.9%
avg -30.8%
ROA
-9.9%
avg -28.5%
Analysis
ROA is currently the strongest return metric at -9.9% versus its period average of -28.5%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Hendrik Scholl | Chief Medical Officer | — | — | 57 | $32,946.00 | 0.08% |
Nathan L. Mata | Chief Scientific Officer | — | — | 60 | $440.00 | <0.01% |
Yu-Hsin Lin | Chairman of the Board of Directors & Chief Executive Officer | — | — | 48 | $182,949.00 | 0.46% |
Hao-Yuan Chuang | Chief Financial Officer & Director | — | — | 42 | $205,264.00 | 0.51% |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
120
$7.07M
Net Sentiment
$7.07M
Net selling
Most Active
MATA NATHAN L.
103 transactions
1–10 of 120
Analysis
Insiders reported 0 buys worth $0.00 and 120 sells worth $7.07M over the last 12 months. That adds up to net selling of $7.07M. MATA NATHAN L. was the most active insider with 103 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A2 analysts |
| Revenue | N/A | N/A | N/A | N/A2 analysts |
| Net Income | N/A | N/A | N/A | N/A2 analysts |
| EBIT | N/A | N/A | N/A | N/A2 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Peer companies in the same sector
Praxis Precision Medicines, Inc.
NASDAQ:PRAX
$5.92B
Ligand Pharmaceuticals Incorporated
NASDAQ:LGND
$5.36B
Mirum Pharmaceuticals, Inc.
NASDAQ:MIRM
$5.29B
Crinetics Pharmaceuticals, Inc.
NASDAQ:CRNX
$3.78B
ACADIA Pharmaceuticals Inc.
NASDAQ:ACAD
$3.71B
Viking Therapeutics, Inc.
NASDAQ:VKTX
$3.61B
Arcutis Biotherapeutics, Inc.
NASDAQ:ARQT
$3.28B
Dyne Therapeutics, Inc.
NASDAQ:DYN
$3.24B
Soleno Therapeutics, Inc.
SLNO
$2.76B
ADMA Biologics, Inc.
NASDAQ:ADMA
$1.97B
Who manages BLTE?
Belite Bio, Inc (BLTE) lists 4 active executives. The top listed executive is Hendrik Scholl, Chief Medical Officer.
Are BLTE insiders buying or selling?
Recent insider activity shows net selling of $5.27M.
Explore More
Continue the stock analysis
Jump to another research area for this company.